Tiny implant which battles skin cancer to begin human trials
Cancer Research UK says that the technique shows 'real potential'
An implant the size of a fingernail that instructs immune cells to home in on and kill cancer cells has been put forward for clinical trials, which scientists hope could revolutionise the treatment of skin cancer.
The novel technique, one of several ground-breaking cancer vaccines in development, could also represent a new direction for treatments of other forms of cancer.
Researchers at Harvard University first trialled the implant in mice four years ago, but have now perfected their technique and received approval for human trials. The implant combats melanoma – the most lethal form of skin cancer.
Half the mice that received two doses of the vaccine showed complete regression of their cancer tumours.
Cancer Research UK said that the technique showed “real potential” to one day add to the growing “arsenal against cancer”.
The implant works like other vaccines by aiding the immune system’s ability to recognise and attack cancer cells. Research in the field of cancer vaccines is still in its early stages, but many scientists believe the techniques carry the potential for many future treatments. After a glut of major breakthroughs in recent years, development of some novel treatments has stalled, but the Harvard device heralds a possible new direction.
“It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Glenn Dranoff, professor of medicine at Harvard Medical School. “We’re beyond thrilled with the momentum, and excited about its potential”.
The Phase I study in humans, which will test if the device is safe for clinical use, is expected to be complete by 2015, so it could be many years before the technique becomes available to patients.
Dr Emma Smith, Cancer Research UK’s senior science communications officer, said: “This is an early stage clinical trial to find out if a skin cancer vaccine is safe for patients, but larger trials will need to be run before we know if it can treat the disease and is better than the treatment that’s currently used. Harnessing our body’s own immune system to attack cancer is showing real potential and these types of novel approaches could mean expanding our arsenal against cancer.”
- 1 Bill Clinton portrait features Monica Lewinsky reference, artist admits
- 2 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 3 Pornhub turns masturbation into energy in bid to save the planet
- 4 Have sex with your iPad thanks to the new sex toy no-one asked for
- 5 Average penis size revealed: Scientists attempt to find what is 'normal' to reassure concerned men
Bill Clinton portrait features Monica Lewinsky reference, artist admits
Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
The 'sex selfie stick' lets you FaceTime the inside of a vagina
Kanye West gives guest lecture at Oxford University: 'If I, Kanye West, can remove my ego, I think there's hope for everyone'
'This is what Islam tells us to do': A rare glimpse inside a Saudi Arabian prison – where Isis terrorists are showered with perks and privileges
New theory could prove how life began and disprove God
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
This is what it's like to be dead, according to a guy who died for a bit
Ukip would cut billions from Scottish budget to fund English tax cuts
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
End of the licence fee: BBC to back radical overhaul of how it is funded
£18000 - £21000 per annum: Recruitment Genius: This company is a customer focu...
£16000 - £18000 per annum: Recruitment Genius: A Business Development Executiv...
£45000 - £53000 per annum + bonus + benefits: Ashdown Group: Learning & Develo...
Negotiable: Recruitment Genius: One of the UK's largest regional newspaper pub...